NEW YORK, Jan. 25, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Global sales of human and animal vaccines reached approximately $25.2 billion in 2009. The market is expected to rise at a compound annual growth rate (CAGR) of 17.9% to reach $64.2 billion by 2015.The global market for human vaccines in 2008 was $18.7 billion and, with a continuing increase in the global market, reached $21.2 billion in 2009. This market is expected to rise at a compound annual growth rate (CAGR) of 19.6% to reach $58.6 billion by the end of 2015.
The animal vaccines market grew from approximately $3.8 billion in 2008 to about $4.0 billion in 2009, an increase of about 5.9%. This market is expected to increase at a 5.7% compound annual growth rate (CAGR) between 2010 and 2015 to reach $5.6 billion in 2015.
INTRODUCTIONSTUDY OBJECTIVESBCC's goal in conducting this study is to provide an overview of the current and future characteristics of the global market for human and animal (veterinary) vaccines and related vaccine technologies. The key objective is to present a comprehensive analysis of the current market and its future direction in the human and animal (veterinary) vaccines market with their utilization and employment in preventing and/or treating infectious diseases.
This report explores present and future strategies within the human and animal (veterinary) vaccines market, including attenuated (live) vaccines, inactivated (killed) vaccines, conjugate vaccines, recombinant/recombinant DNA (rDNA) vaccines, subunit vaccines, toxoid vaccines, and combination vaccines. The current state of the market, the setbacks, the innovations, and the future needs of the market are discussed in this report. A general overview of vaccines, and related technologies used currently and in the past are discussed in the report.
A detailed analysis of the vaccine industry structure has been conducted. This includes all seven major categories of vaccines broken down by market share belonging to leading manufacturers and/or suppliers. Revenues for each of the seven categories of vaccines are broken down by region. Sales figures are estimated for the 5–year period from 2010 through 2015.
Applications for human and animal (veterinary) vaccines, as to their prophylactic or therapeutic use are also discussed separately in the report, with emphasis in the meningococcal/pneumococcal vaccines, influenza vaccines, pediatric vaccines, adult/adolescent vaccines, travel vaccines, and others. The report also includes significant patents and their allotments in each vaccine technology category.
REASONS FOR DOING THIS STUDYThis study was conducted to provide vital and detailed information regarding human and animal (veterinary) vaccines. The vaccines industry is experiencing growth due to new products hitting the market as well as a general increase in public awareness and more standardized immunization schedules. This study was conducted to provide detailed market analysis of human and animal (veterinary) vaccines along with the different factors affecting this market. While the vaccines market was affected by the global economic downturn, it retained steady growth and new developments are expected to further influence the market.
Acquisitions, mergers, and alliances by companies and global organizations are covered in this report. The study also discusses the strengths and weaknesses of each category of vaccines in addition to any new technologies/developments, manufacturer/supplier competition, as well as changing immunization coverage rates.
INTENDED AUDIENCEThis study contributes to the areas of market growth in preventing some disease types through vaccination from the point of view of manufacturers and users. Clinicians, physicians, the pharmaceutical and biopharmaceutical industries, hospitals and research institutes will find this study to be of interest.
SCOPE OF THE STUDYThe scope of this study encompasses the vaccine human and animal (veterinary) markets. BCC analyzes each market and its applications by its need for disease type requiring vaccination, regulatory environment, technology involved, market projections, and market share. Technological issues include the latest trends and developments.
METHODOLOGYBoth primary and secondary research methodologies were used in preparing this study. BCC conducted a comprehensive literature search, which included technical newsletters and journals, and many other sources. Data were collected through interviews and correspondence with various analytical/chemical/pharmaceutical/biotechnical experts. Projections were based on estimates such as the current number of end users, potential end users, mergers and acquisitions, and market trends.
INFORMATION SOURCESMany companies within the industry were surveyed to obtain data for this study. Included were manufacturers and end users of pharmaceuticals. Data were gathered from various industry sources. BCC spoke with officials and physicians within the industry, consulted newsletters, company literature, product literature, and a host of technical articles, journals, indexes, and abstracts. Exhaustive investigations of databases by key terminology were completed. In addition, data were compiled from current financial, trade, and government sources.
ABOUT THE AUTHORThe study has been carried out by a team of professionals in the biotechnology industry. The project manager is Shalini S. Dewan, who holds a master's degree in Pharmaceutical Chemistry and has over 14 years of industry experience. Among the research topics she has covered are studies on compounds of potential pharmaceutical interest from ibuprofen and 2–naphthyl acetic acid. Shalini was awarded a Gold Medal by the Prime Minister of India for her work and has worked with top companies in both India and the U.S. Some of her other reports with BCC are Reagents of Chromatography; Spectroscopy, an Enduring Market; Advanced Drug Delivery Systems: New Developments, New Technologies; Orthopedic Drugs, Implants and Devices; Medical Imaging Reagents and Analysis Equipment; Pharmaceutical Regulatory Industry; The Dynamic Media, Sera and Reagent Market in Biotechnology; Contract Pharmaceutical Manufacturing, Research and Packaging; Chiral Technology: Global Markets; Autacoids and Related Drugs: Technologies and Global Markets; Contraceptives: Technologies and Global Markets; Liver Disease Treatments: The Global Market; Hormone Replacement Therapies and Other Hormone Therapies: Global Markets; Cardiovascular Medicine: Diagnostics, Drugs and Devices; and Cancer Therapies: Technologies and Global Markets.
The lead consultant for this project was Ms. Taruna Chhabra, who holds a Bachelor's of Science in Biology and is a member of the National Honor Society for Biological Sciences (BBB).
To order this report:: Vaccine Technologies and Global Markets
Copyright©2010 PR Newswire.
All rights reserved